Suven Life Sciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, will present three posters at SLEEP- 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), LLC (APSS) being held at Baltimore, USA during June 14-17, 2026. The presentations will showcase the clinical advancement of Samelisant, including positive Phase 2 efficacy data in excessive daytime sleepiness (EDS), the rationale and design of a Phase 2 study for cataplexy in Type 1 narcolepsy, and the Phase 3 development strategy for Samelisant in patients with narcolepsy. The APSS is a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. The SLEEP meeting is the premier clinical and scientific meeting focused on sleep medicine, sleep and circadian research, and sleep health, a release said. Published on June 12, 2026